BRCA1 and breast cancer: Olaparib, the first FDA-approved inhibitor of poly(ADP-ribose)-polymerase (PARP), was initially used for BRCA-deficient ovarian cancer and later approved for HER2-negative BC with BRCA1/2 mutations.